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Summary
Introduction: Prescribing opium, morphine and heroin to opiate addicts has a long history, as an approach to prevent 
negative consequences from excessive and uncontrolled use. It rarely reached the majority of this target population. Dur-
ing the 20th century, moral concerns mainly led to control measures and total prohibition (except for medicinal use and re-
search). Other opioid agonists replaced opiates for maintenance therapy; Methadone and Buprenorphine maintenance be-
came the preferred approaches to reach out effectively heroin addicts and to allow for significant improvements in health 
and social status of patients. Their role for the treatment system is essential. Aim: to describe the revival, role and function 
of heroin-assisted treatment (HAT), and to review critical concerns against this approach in the light of research evidence. 
Methods: research reports, reviews and monographs on opiates, agonist maintenance treatment and HAT. Results: The 
extent of HAT in countries where it is available is modest, in comparison to other agonist maintenance treatments for opi-
ate dependence. Within the European Union, the role of HAT is marginal. A range of therapeutic, safety, prevention and 
economic concerns about potential negative effects of HAT, for patients and for the treatment system, are discussed in 
the light of relevant research evidence. None of the concerns is justified. Positive effects for the treatment system and for 
public order prevail. Conclusions: the present model of HAT has good outcomes for previously treatment-resistent heroin 
addicts, is a safe and cost-effective therapy and a useful element in a comprehensive treatment system for heroin addicts.
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1. Introduction: opiates for opiate addicts
The idea and the practice of providing opiates to 
people dependent on opiates are not new. The wide-
spread use of opium as an analgesic leading to what 
we term a dependence syndrome in chronic patients 
dates back to antiquity, and examples of maintenance 
regimes became known early in the 20th century [32]. 
Following the extraction of morphine and the inven-
tion of hypodermic injections, opiate analgesia be-
came more effective and widely used, the incidence 
of the dependence syndrome rose, and led to the 
practice of prescribing morphine to those who were 
dependent. When heroin (diacetylmorphine) was dis-
covered, it not only found use as a replacement for 
morphine; it became a component in so-called pat-
ent medicines that were prescribed in great quantities. 
This resulted in its extended use and first observations 
of heroin dependence – and again in regimes that are 
based on prescribing the substance for treatment and 
maintenance [4, 18, 23, 27, 31]. 
The reaction against any use of heroin was not 
so much based on scientific data about the shortcom-
ings or negative effects of such use. It mainly came 
from moralistic concerns that demonized heroin as a 
threat to society and heroin addicts as criminals. The 
result was a stepwise process of control measures [20, 
26]. This process finally led to prohibition worldwide, 
as stated in the UN Single Convention on Narcotic 
Drugs [34]. In 9 countries only, heroin was still le-
gally prescribed as medicine [16], and its prescription 
to heroin addicts became a British specialty [16, 26].
Other forms of agonist maintenance treatment of 
opiate dependence started in Canada and USA with 
the prescription of oral methadone. Later on, a diver-
sification took place, with the use of buprenorphine, 
codeine and morphine as orally applicable opioid 
medications for illegal opiates, and the practice of 
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writing out prescriptions to addicts was replaced by 
more comprehensive care programmes. This model 
became the most cost-effective treatment for opioid 
dependence, and was recommended as forming the 
“backbone of the treatment system for opioid depend-
ence” [37]. However, an ideological debate on main-
tenance treatment as an ethically unacceptable tool 
continued, and the dispute between abstinence-only 
and agonist maintenance therapies gave way only re-
cently to an integrative concept of opioid dependence 
treatment [33].
2. The role of opioid maintenance therapy at 
the system level
Reliable data on the proportion of opiate addicts 
covered by maintenance regimes in history are rare. 
Apparently, even in countries with traditional avail-
ability of opium, such regimes were not widespread 
(for South-east Asia see [35], for England see [2]). 
Narcotic clinics in the USA attracted a small percent-
age of the rapidly increasing addict population [19]. 
In contrast, the percentage of heroin addicts covered 
by prescribing practitioners and specialized clinics in 
England was probably rather high; according to Home 
Office data, 1,288 out of 1,418 registered narcotic ad-
dicts were in outpatient treatment by the end of 1972, 
and it is reasonable to presume that a large majority 
of outpatient treatment consisted in maintenance re-
gimes [16]. In recent years, a high proportion of cov-
erage is documented in some member states of the 
European Union by agonist maintenance treatments, 
mainly using methadone and/or buprenorphine. Cov-
erage throughout the Union was ca. 700,000 out of 
1.3 million heroin addicts by 2009 [6].
3. A revival of heroin prescription for 
maintenance
Why should heroin be taken up again as a medi-
cation in maintenance treatment? Two reasons must 
be mentioned here: first, the advent of the HIV epi-
demic among injecting addicts raised serious public 
health concerns; the intimate partners of injectors 
are at high risk of becoming infected and thereby a 
threat to the population at large. Second, the grow-
ing numbers of heroin addicts for whom other agonist 
maintenance treatments failed increased with the total 
numbers enrolled in such maintenance, and there was 
need for an attractive alternative. 
Lastly, a competitive and aggressive heroin mar-
ket as well as a rapidly increasing number of mar-
ginalized heroin injectors, culminated in large open 
drug scenes in major cities and resulted in creating 
an unacceptable public nuisance. This highly visible 
indicator of an inefficient drug policy called for a new 
orientation. In 1991, the Swiss Federal Government 
issued a new drug policy, which included harm re-
duction measures, as well as innovative approaches 
in prevention, treatment and law enforcement. One 
of the innovations was a national research project on 
HAT, based on a new model of supervised heroin in-
jecting in the framework of a comprehensive assess-
ment and therapeutic programme. 
4. The Swiss model of HAT: learning from 
history
When preparing the Swiss national study, for-
mer experiences with this approach had to be consid-
ered. British heroin prescribing had adapted consider-
ably to the changed characteristics of patients, among 
whom there were by then many young marginal in-
jectors instead of socially integrated pain patients 
with iatrogenic heroin dependence. The adaptation 
consisted in mailing prescriptions directly to pharma-
cies instead of handing them out to patients, regular 
consultations, urine control, dosing restrictions. Cen-
tral registration made it difficult to get prescriptions 
from multiple doctors. “The structural transforma-
tions brought about by the clinics have enabled the 
growth of the therapeutic essential – a relationship 
between doctor and addict in which both must expect 
that they will be working together over months and 
years” [16]. The obligation to notify patients receiv-
ing heroin for a central registry was suspended in 
1997 [18].
The narcotic clinics in the southern states of the 
USA with rather socially integrated patients and well 
structured programmes were effective, whereas clin-
ics in urban areas in the North suffered from prob-
lems with large numbers of illegal injectors involved 
in criminal activities [19]. 
When the Swiss Federal Government agreed to 
start a scientific project with heroin-assisted treat-
ment, this had to reach out to the disintegrated young 
injectors in the large open drug scenes in urban areas. 
The justification came from public health and public 
order concerns. Positive results were not only expect-
ed for the benefit of addicts; the main objective was 
to improve an intolerable situation aiming at effects at 
population level. The Federal Drug Commission re-
ceived the mandate to prepare such a project, and one 
of the first steps taken was to ask Dr. Mino to write a 
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review of all former experiences with heroin and mor-
phine prescribing. In her report, she concluded with 
a number of recommendations drawn from her pre-
vious experience. She firmly recommended criteria 
providing indications based on the given epidemio-
logical and therapeutic situation, a defined indication 
process and intake procedure, prescribing heroin in 
public clinics only, with small-scale experiments to 
be evaluated after 2 years [19]. 
On the basis of her recommendations, the re-
search protocol for the Swiss cohort study was set up, 
discussed and approved in the Federal Narcotic Com-
mission, the National Health Authorities, and lastly 
at Federal Government level. This process resulted in 
the following main characteristics of the project [34]: 
Restrictive indication criteria (only for chronic 
opiate-dependent patients for whom other treatments 
had failed repeatedly, and who are suffering from 
health and/or social deficits, minimal age (20 years), 
minimal documented duration of heroin dependence 
(2 years);
• Centralized intake procedure (at Federal Of-
fice of Public Health);
• Centrally authorized outpatient clinics only 
with multi-disciplinary teams;
• Supervision and continued education of 
teams;
• The framework of a comprehensive assess-
ment and therapeutic programme;
• A needs-based individual regime;
• The strictly supervised intake of injectable 
opiates;
• Driving of motor vehicles not permitted;
• Exclusion of simultaneous enrollment in an-
other heroin substitution programme;
• Consent of patients and staff to providing all 
the data and examinations required for the 
evaluation process.
An independent international expert group of 
experts, nominated by WHO, controlled the imple-
mentation, and commented on the evaluation report, 
suggesting more randomized controlled studies [1]. 
Following their recommendations, the Swiss model 
of HAT was subsequently used in the Netherlands, 
Germany, Spain, Canada and England, in randomized 
controlled trials. The characteristics and the positive 
outcomes of all trials have been published in great 
detail [28, 29]. Significant improvements in health 
and social integration, which were superior in experi-
mental groups compared with control groups, made 
HAT an interesting additional approach for treatment-
refractory heroin addicts. How well is it accepted as 
part of the treatment system?
5. Extent of HAT at the treatment system level
 First, we should look at the extent of traditional 
heroin prescribing in the UK. A 1995 survey of drug 
services commented on the current practice of heroin 
prescription. The Home Office recorded 55 current 
heroin licenses. The majority of doctors wrote pre-
scriptions for only a few patients. The total number 
of patients was 323 [8]. A survey published in 2001 
showed that, of 70 doctors who had a licence for pre-
scribing heroin, only 47 made use of it. The licence is 
available through the Home Office and only for spe-
cialized psychiatrists working in public clinics; it is 
valid for 3 years. The obligation to enroll patients re-
ceiving heroin in a central registry was suspended in 
1997. Existing guidelines for heroin maintenance no 
longer supply details. There are no defined indication 
criteria. However, as a rule, patients had tried other 
treatments previously and documented an extended 
career of heroin dependence [18, 27].
What is the present situation in countries where 
trials with supervised injected heroin took place, and 
at the European level?
HAT is provided as a regular treatment for oth-
erwise treatment-refractory heroin addicts in Den-
mark, Germany, the Netherlands and Switzerland. In 
these countries, HAT clinics are part of the regular 
treatment system. In Spain and Canada, patients for-
merly involved in trials in their respective countries 
may continue to receive HAT, but no new patients are 
being admitted. The future of the English clinics de-
pends on local funding after the end of national fund-
ing. Up to now, Denmark is the only country starting 
HAT as a regular treatment without previously con-
ducting a research project (in view of the evidence 
coming from trials in other countries). 
The capacity of HAT is minimal, at best mod-
est when compared with the total capacity of agonist 
maintenance treatment for opioid dependence (Table 
1). Based on the currently available information, HAT 
is provided in 58 clinics located in 8 countries, but to 
less than 1% of all patients in agonist maintenance 
treatment in those countries. Even in Switzerland, 
which has 23 HAT clinics (2 of them within prisons), 
the percentage is only 9%. 
In countries belonging to the European Union, 
the extent of HAT is still modest (Figure 1) An es-
timated total of ca. 700,000 heroin addicts receive 
some kind of agonist maintenance treatment; this 
covers more than 50% of people with opioid depend-
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ence. The agonist medications are methadone (69%), 
buprenorphine (28%) and morphine/heroin (3%). 
Agonist maintenance treatment for prison inmates 
is available in 26 of the 30 countries monitored by 
the European Monitoring Centre for Drugs and Drug 
Abuse (EMCDDA); none of these is providing HAT 
to opioid-dependent prison inmates [7].
The relatively low numbers of opioid addicts 
receiving HAT is partly due to restrictive entry crite-
ria: the target group is defined as treatment-refractory 
(other treatments must have failed repeatedly), and as 
suffering from major health and/or social deficits. But 
this target group is more numerous than the patients 
enrolled in HAT. How can this be explained?
In spite of the encouraging outcomes, concerns 
about and opposition to HAT were and remain con-
siderable. It is worth looking at these concerns in the 
light of empirical outcome data.
6. The range of concerns against heroin-
assisted treatment
The range of concerns covers therapeutic, eco-
nomic and safety aspects, as well as negative conse-
quences for prevention and other treatments:
• «Limitless hunger»: the demand for increas-
ing dosages; 
• «Hooked forever»: indicating the weaken-
ing of the will to recover; 
• Increase of heroin-related mortality and 
Table. 1 Total capacity of HAT
Country Nr of HAT clin-ics
Total 
capacity Nr patients in AOT % HAT of all AOT
Canada 2 140 14,700 (BC only) 0.9
Denmark 5 300 7,600 0.02
England 3 100 147,640 0.007
Germany 7 300 77,300 0.7
Netherlands 18 745 8,185 (MMT only) (9.0)
Spain 1 56 69,111 0.001
Switzerland 23 1‘600 18,000 9.0
Belgium (1) ? 17,482 ?
Total 58 3‘095 Ca. 360‘018 Ca. 0.86
Sources: [28], European Drug Report 2015, personal communications (2013 data); AOT=Agonist Opioid Treatment
Figure 1. Capacity of HAT in the European Union
Source: European Drug Report 2015 (2013 data) 
28
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morbidity; 
• Deviation of prescribed heroin to the illegal 
market; 
• Lower threshold for starting heroin use, seen 
as sending the «wrong message»; 
• Negative impact on other treatment ap-
proaches; 
• Waste of financial and human resources.
6.1. Therapeutic concerns in the light of facts
The main therapeutic concerns are clearly not 
justified when confronted with outcome data from the 
Swiss national cohort study. The average daily dos-
ages increased slightly during the induction phase, 
due to a careful testing of the individually appropriate 
dose; this was followed by a stabilization over about 
4 months and a decrease after 8 months in treatment 
[24]. Also, when considering the various regimes of 
medications (i.v. heroin only, combined with heroin 
that is smoked or oral methadone), the mean dose for 
injectable heroin decreased significantly over time 
[11].
The treatment retention curve shows a continued 
decrease over 6 years; after about 3 years, half of the 
patients had left the programme [24].
Conclusion 1: therapeutic concerns about ever-
increasing dosages and permanent retention are not 
confirmed by outcome data.
6.2. Concerns and facts about medical safety
Concerns about medical safety were further 
contradicted by outcome data from the Swiss cohort 
study. Mortality was definitely less than that in heroin 
addicts out of treatment, as also when compared her-
oin addicts in methadone treatment. Not a single case 
of death from prescribed heroin alone occurred, while 
there were a few cases of death due to mixed intoxi-
cation and overdose [25]. Infectious diseases related 
to intravenous injecting decreased; pre-existing infec-
tions received adequate treatment, and new infections 
were extremely rare, due to the reduction in illegal 
injections [29, 33].
Treatment outcomes with regard to health sta-
tus and social integration in the Swiss cohort study 
show significant improvements in general and mental 
health status, in nutritional status (body mass index) 
and in injection-related skin disease [24]. Pregnancy 
and childbirth while being enrolled in HAT were re-
peatedly documented and did not present problems. 
One spontaneous abortion occurred when a patient 
started to withdraw from heroin. No malformation in 
the chidren was seen, and there was no case of sudden 
infant death [10].
Of those who left the programme, a substantial 
proportion went to follow-up treatments. According to 
the 3-year-follow up data, 37% changed to methadone 
or buprenorphine maintenance and 22% to drug-free 
treatment, while 15% dropped out of the programme. 
The other cases of dropout were due to hospitaliza-
tion, imprisonment or death [24]. At 6-year follow 
up, patients who had left the programme showed a 
continued significant reduction of illicit substance use 
and criminal behaviour compared with entry data, as 
well as patients still in treatment [12].
Side-effects of HAT were systematically record-
ed in the Swiss cohort study and reported to a safety 
monitoring/group of experts. Histamin-like skin reac-
tions, dizziness, respiratory difficulties, myoclonus, 
sedation – mostly mild and transient – were recorded; 
even in the few exceptional cases that occurred, they 
only led to a discontinuation of treatment [14]. In a 
few other cases, epileptic seizures occurred and were 
thoroughly investigated; in some cases, pre-existing 
epilepsy was documented [15]. A transient cerebral 
hypoxemy may cause seizure but can be prevented if 
patients do not lie down, but, rather, walk around for 
a while after injection.
Conclusion 2: HAT outcomes include a range 
of positive effects on somatic and psychiatric condi-
tions, and reduce mortality and infection rates, but 
any side-effects of injected heroin must be taken care 
of through staff training and clinical practice.
6.3. Concerns about misuse of prescribed heroin
The removal of prepared heroin dosages that are 
then given to other addicts or sold on the black market 
is prevented through strict direct observation of injec-
tions by staff in the clinics, and clinics have to store 
heroin in safes to prevent stealing. Police staff have 
not reported any diversion of heroin from clinics.
Conclusion 3: no reports are available on the di-
version of prescribed heroin to illicit use.
6.4. Concerns about public safety
Patients enrolled in HAT show a rapid and per-
sistent significant decrease in criminal involvement 
and in small-scale drug trafficking [17]. In addition, 
typical drug-related delinquency in Swiss cities has 
declined significantly [17]. An increase in traffic ac-
cidents was prevented by the rule that patients had 
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to deposit their driving license during enrollment in 
HAT.
Conclusion 4: HAT results in an improvement of 
public safety.
6.5. Concerns about negative impact on other 
treatment approaches
A decline of applications for drug-free and 
methadone-assisted treatments was unlikely, due to 
the restrictive rule excluding all heroin addicts from 
the programme who had not repeatedly tried other 
treatments before. As a result, entries to drug-free 
treatment in Switzerland remained stable after the 
initiation of HAT, and entries to methadone-assisted 
treatment increased (Table 2). Also, the introduction 
of HAT contributed to an increased awareness of qual-
ity in addiction treatment, and drug-free residential 
treatment. In addition, methadone maintenance treat-
ment benefited from the referral of non-compliant pa-
tients with continued illicit heroin use to HAT [31].
Data from the randomized controlled studies 
showed no preference given to heroin addicts over 
conventional treatments [29].
Conclusion 5: HAT does not undermine other 
approaches to the treatment of opioid dependence.
6.6. Prevention concerns
Did prescribing heroin as a medicine send the 
’wrong message’ to young people, inviting more ex-
perimentation with the substance? As a matter of fact, 
the incidence of new heroin users fell dramatically, to 
values recorded in the early 1970s before the heroin 
epidemic got out of control [21]. 
In discos, clubs, at raves, a vast range of drugs 
is available and consumed, but heroin is hardly ever 
on the list. 
Conclusion 6: HAT has not lowered the thresh-
old for starting heroin use; instead, its image became 
unattractive.
6.7. Economic concerns
HAT is more expensive than methadone-assisted 
treatment, due to the need to run the clinics involved 
all year long, including weekends and holidays. Are 
the expenses justified in the light of economic gains? 
Data from cost-benefit studies are available to answer 
the question.
Under experimental conditions, the economic 
evaluation of the German and the Dutch trials docu-
mented a great many benefits. The Dutch study found 
cost-effectiveness for the specific target group re-
cruited to the trials [5]. Economic evaluation of the 
German trials came to the same conclusion of cost-ef-
fectiveness for experimental and control groups, and 
higher benefits for the experimental group [36]. Cost-
effectiveness is also confirmed for the Canadian trial 
[22], and better cost-effectiveness in the experimental 
group for the RIOTT trial in England [3]. In addition, 
the Swiss prospective cohort study documented two-
fold benefits compared with costs for HAT [13]. In all 
these studies, reduced health costs and law enforce-
ment costs since entering HAT made primary contri-
butions to the benefits.
Conclusion 7: although more expensive than 
oral maintenance treatments, HAT has proven its 
cost-effectiveness, and its superiority over control 
groups in randomized trials, so demonstrating that it 
is a good investment.
6.8. Continued concerns expressed against wider 
use of HAT
In spite of all this evidence, caution about ex-
tending HAT continues. How can this be understood? 
A detailed review identified the concerns as follows 
[28] about the adequacy of the scientific evidence
• Concerns about security, public safety, and 
potential for diversion and abuse
• Concern about rebound damage to other 
treatments, such as oral MMT and rehabili-
tation; 
• Financial costs; 
Table 2. Evolution of the Swiss treatment system since starting HAT
1996 2000 2004 2008 2014
Drug-free residential 1,250* 1,3390 1,175 1,091 981
Methadone
maintenance 12,000* 18,393 15,300 18,052 17,008
HAT 1,000* 1,240 1,515 1,449 1,656
Source: ISGF
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St. Martin’s Press, London.
3. Byford S, Barrett B, Metrebian N, Groshkova T, Cary 
M, Charles V, Lintzeris N, Strang J (2013): Cost-
effectiveness of injectable opioid treatment vs. oral 
methadone for chronic heroin addiction. BJPsych 1–9. 
doi: 10.1192/bjp.bp.112.111583
4. De Ridder M (2000): Heroin. Vom Arzneimittel zur 
Droge. Campus, Frankfurt/Main.
5. Dijkgraaf MG, van der Zanden BP, de Borgie CA, 
Blanken P, van Ree JM, van den Brink W (2005): Cost 
utility analysis of co-prescribed heroin compared with 
methadone maintenance treatment in heroin addicts in 
two randomized trials. BMJ 330: 1297.
6. EMCDDA (2011): Drug Report 2011. The State of the 
Drugs Problem in Europe. European Monitoring Centre 
for Dugs and Drug Addiction, printed in Luxemburg.
7. EMCDDA (2015):  European Drug Report: 
http://www.emcdda.europa.eu/publications/edr/
trendsdevelopments/2015/online/start
8. Farrell M, Hall W (2015): Heroin-assisted treatment: 
has a controversial treatment come of age? Editorial 
BJPsych 207:3
9. Ferri M, Davoli M, Perucci CA (2011): Heroin 
maintenance for chronic heroin-dependent individuals. 
Cochrane Database Syst Rev 2011; 12: CD003410. 
10. Geistlich S (1997): Schwangerschaftsverlauf und 
Entzugssymptome Neugeborener in der diversifizierten 
Opiatabgabe. Institut für Suchtforschung, Zürich
11. Gschwend P, Rehm J, Blättler R, Steffen T, Seidenberg 
A, Christen S, Bürki C, Gutzwiller F (2004): Dosage 
Regimes in the Prescription of Heroin and Other 
Narcotics to Chronic Opioid Addicts in Switzerland – 
Swiss National Cohort Study. Eur Addict Res 10: 41-48.
12. Güttinger F, Gschwend P, Schulte B, Rehm J, 
Uchtenhagen A (2003). Evaluating Long-Term Effects 
of Heroin-Assisted Treatment: The Results of a 6-Year 
Follow-Up. Eur Addict Res 9:73-79
13. Gutzwiller F, Steffen T (Eds.) (2000): Cost-Benefit 
Analysis of Heroin Maintenance Treatment. Karger, 
Basel.
14. Haemmig R (1997): Hochdosiertes intravenöses Heroin 
versus intravenöses Morphin bei Drogenabhängigen. 
Eine randomisierte, kontrollierte Doppelblindstudie 
mit Crossover. Report to the Federal Office of Public 
Health, Bern.
15. Hug J, Kocher R, Stohler R, Ladewig D (1997). 
Das Auftreten von epileptiformen Störungen bei 
opiatabhängigen Patienten unter intravenöser 
Substitutionstherapie mit Heroin, Morphin und 
Methadon. Psychiatric University Hospital, Basel.
16. Judson HF (1973): Heroin Addiction in Britain. Harcourt 
Brace Jovanovich, London.
17. Killias M, Aebi M, Ribeaud D (1999): Prescription 
• Hijacking by campaigning groups;
• Diamorphophobia; 
• Safety. 
While four of these concerns are dealt with 
above and their arguments are further invalidated by 
findings from the RCT studies, three new concerns 
appear here. The adequacy of scientific evidence is 
supported by the methodology used in the trials and 
by the data on sustained benefits; questions remaining 
open are mentioned and more research is now needed 
to improve understanding of the remission processes, 
the quality of life and social functioning of these pa-
tients. 
A misinterpretation of the trials as being the first 
steps towards legalization must be prevented by clear 
and unambiguous information that will discourage 
such misinterpretation. Lastly, the prevailing image 
of heroin as a substance that is rightfully prohibited 
has replaced all the experience gained with the sub-
stance as a powerful medicine, especially in analge-
sia, after it has been used, in particular, in the UK for 
over a century. 
As in the Swiss study, in all randomized con-
trolled trials the advent of notable side-effects (most-
ly respiratory depression, at a rate of about 1 per 
6,000 injections) was significantly more frequent in 
the experimental groups than in the control groups, 
therfore requiring adequate clinical observation and 
intervention skills [9, 28]. It may be added here that 
non-injectable preparations – whether smoked, intra-
nasal or oral (either through immediate or slow re-
lease) – were introduced for patients who presented 
problems with injecting, or who preferred alternative 
routes of application; so far, severe events have not 
been documented. 
The overall conclusion of the authors is clear; 
“This intensive intervention is for a patient popula-
tion previously considered unresponsive to treatment. 
Inclusion of this low-volume, high-intensity treat-
ment can now improve the impact of comprehensive 
healthcare provision” [29]. 
There is not much to add. Integrating HAT as 
part of a comprehensive system for the treatment of 
opioid dependence is in the interest of public health 
and public order, besides being in the interest of oth-
erwise treatment-resistent heroin addicts.
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